The price-to-earnings ratio for Puma Biotechnology Inc (NASDAQ: PBYI) is above average at 4.44x. The 36-month beta value for PBYI is also noteworthy at 1.29. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for PBYI is 38.86M, and at present, short sellers hold a 7.42% of that float. The average trading volume of PBYI on April 11, 2025 was 425.00K shares.
PBYI) stock’s latest price update
Puma Biotechnology Inc (NASDAQ: PBYI) has experienced a decline in its stock price by -1.09 compared to its previous closing price of 2.74. However, the company has seen a fall of -6.55% in its stock price over the last five trading days. businesswire.com reported 2025-04-02 that LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology announced that inducement awards were granted to staff hired in March, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).
PBYI’s Market Performance
Puma Biotechnology Inc (PBYI) has seen a -6.55% fall in stock performance for the week, with a -18.86% decline in the past month and a -18.13% plunge in the past quarter. The volatility ratio for the week is 8.43%, and the volatility levels for the past 30 days are at 6.44% for PBYI.. The simple moving average for the past 20 days is -12.43% for PBYI’s stock, with a -10.14% simple moving average for the past 200 days.
Analysts’ Opinion of PBYI
Many brokerage firms have already submitted their reports for PBYI stocks, with Citigroup repeating the rating for PBYI by listing it as a “Buy.” The predicted price for PBYI in the upcoming period, according to Citigroup is $11 based on the research report published on September 28, 2021 of the previous year 2021.
BofA/Merrill, on the other hand, stated in their research note that they expect to see PBYI reach a price target of $9. The rating they have provided for PBYI stocks is “Underperform” according to the report published on June 25th, 2020.
Goldman gave a rating of “Sell” to PBYI, setting the target price at $8 in the report published on October 08th of the previous year.
PBYI Trading at -12.10% from the 50-Day Moving Average
After a stumble in the market that brought PBYI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.04% of loss for the given period.
Volatility was left at 6.44%, however, over the last 30 days, the volatility rate increased by 8.43%, as shares sank -18.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.02% lower at present.
During the last 5 trading sessions, PBYI fell by -6.72%, which changed the moving average for the period of 200-days by -8.61% in comparison to the 20-day moving average, which settled at $3.09. In addition, Puma Biotechnology Inc saw -11.15% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PBYI starting from NOUGUES MAXIMO F, who sale 10,227 shares at the price of $3.15 back on Jan 02 ’25. After this action, NOUGUES MAXIMO F now owns 152,295 shares of Puma Biotechnology Inc, valued at $32,232 using the latest closing price.
Ludwig Jeffrey Jerome, the Chief Commercial Officer of Puma Biotechnology Inc, sale 9,437 shares at $3.15 during a trade that took place back on Jan 02 ’25, which means that Ludwig Jeffrey Jerome is holding 108,951 shares at $29,743 based on the most recent closing price.
Stock Fundamentals for PBYI
Current profitability levels for the company are sitting at:
- 0.13 for the present operating margin
- 0.72 for the gross margin
The net margin for Puma Biotechnology Inc stands at 0.13. The total capital return value is set at 0.26. Equity return is now at value 41.60, with 13.60 for asset returns.
Based on Puma Biotechnology Inc (PBYI), the company’s capital structure generated 0.45 points at debt to capital in total, while cash flow to debt ratio is standing at 0.53. The debt to equity ratio resting at 0.8. The interest coverage ratio of the stock is 2.49.
Currently, EBITDA for the company is 48.08 million with net debt to EBITDA at 0.1. When we switch over and look at the enterprise to sales, we see a ratio of 0.61. The receivables turnover for the company is 7.2for trailing twelve months and the total asset turnover is 1.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.54.
Conclusion
In summary, Puma Biotechnology Inc (PBYI) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
